Selected publications
-
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
World Journal of Urology.
2018
Academic Article
GET IT
Times cited: 3 -
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma.
Journal of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 122 -
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
The Lancet.
2017
Academic Article
GET IT
Times cited: 53 -
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Clinical Genitourinary Cancer.
2017
Academic Article
GET IT
Times cited: 6 -
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
European Urology.
2017
Academic Article
GET IT
Times cited: 25 -
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
European Urology Focus.
2017
Academic Article
GET IT
Times cited: 2 -
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 42 -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Drug Design, Development and Therapy.
2015
Review
GET IT
Times cited: 22 -
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial.
The Lancet Oncology.
2015
Academic Article
GET IT
Times cited: 100 -
Serum glucose and risk of cancer: A meta-analysis.
BMC Cancer.
2014
Review
GET IT
Times cited: 10